Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study

We found that the use of allopurinol and benzbromarone, whether alone or in combination, had a linear dose-response relationship between the numbers of defined daily doses and the risk of CAD, especially in higher DDDs.